Ogilvie G K, Obradovich J E, Cooper M F, Walters L M, Salman M D, Boone T C
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins 80523.
J Vet Intern Med. 1992 Jan-Feb;6(1):44-7. doi: 10.1111/j.1939-1676.1992.tb00985.x.
Ten dogs were given mitoxantrone at a dose of 5 mg/m2 body surface area intravenously. Recombinant canine granulocyte colony-stimulating factor (rcG-CSF) was administered subcutaneously daily for 20 days after an infusion of mitoxantrone in five of these dogs to determine the effect of the hematopoietic growth factor on the duration and severity of myelosuppression. The median neutrophil counts dropped below normal (less than 3,000/uL) for 2 days in the dogs that received rcG-CSF, and for 5 days in the dogs that received only mitoxantrone. Four of five dogs not treated with rcG-CSF and none of those receiving rcG-CSF developed serious neutropenia (less than 1,500/uL). The neutrophil counts were significantly (P less than 0.05) higher in the rcG-CSF treated dogs at all time points except before the administration of the colony-stimulating factor, and the sixth day after the mitoxantrone was administered. These findings demonstrate that rcG-CSF is capable of reducing the duration and severity of mitoxantrone-induced myelosuppression.
给10只狗静脉注射米托蒽醌，剂量为5mg/m²体表面积。其中5只狗在输注米托蒽醌后，每天皮下注射重组犬粒细胞集落刺激因子（rcG-CSF），持续20天，以确定造血生长因子对骨髓抑制持续时间和严重程度的影响。接受rcG-CSF的狗中性粒细胞计数中位数低于正常水平（低于3000/μL）的天数为2天，而仅接受米托蒽醌的狗为5天。未接受rcG-CSF治疗的5只狗中有4只出现严重中性粒细胞减少（低于1500/μL），而接受rcG-CSF治疗的狗均未出现。除了在给予集落刺激因子之前以及给予米托蒽醌后的第6天，在所有时间点接受rcG-CSF治疗的狗的中性粒细胞计数均显著更高（P<0.05）。这些发现表明，rcG-CSF能够缩短米托蒽醌诱导的骨髓抑制的持续时间并减轻其严重程度。
